Pinto Beans & Penny Stocks 2020 (BEAN)

[Golden Cross]

$ILLR Triller is changing the game AGAIN and again and again and again. The next generation AI-powered,
social media AND live streaming event destination.
https://www.youtube.com/watch?v=CXxzJFmMIE0

[Golden Cross]

💲 $ILLR Opportunity to Leverage ILLR’s Underutilized Assets to Create Next-Gen Entertainment Platform

[ProfitScout]

$BEAT News: HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards

Company Receives Top Honors in the ‘Home Health Diagnostic’ Category for its Groundbreaking Technology that Captures the Heart’s Electrical Signals from Three Dimensions

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced today its selection as a winner of the 2024 Digital Health Hub Awards, hosted by The Digital Health Hub Foundation. Chief Executive Officer Rob Eno accepted the Rising Star award in the ‘Home Health Diagnostic’ category during the renowned HLTH global healthcare conference.

“One of the main challenges in cardiac care is helping patients get the care they need in a timelier manner to prevent worse outcomes or an increased risk of death. This award is a validation of our dedicated team’s hard work to deliver a simple way for patients to capture high-fidelity ECG signals wherever they are when symptoms occur to minimize any delays in care,” commented Mr. Eno.

The recognition highlights HeartBeam’s use of cutting-edge digital innovations to achieve its mission of unlocking a more personalized approach to cardiac care. HeartBeam’s groundbreaking vector-based technology captures the heart’s electrical signals from three dimensions to provide total heart intelligence. By leveraging AI to analyze the data-rich signals, the Company believes it will be able to unlock a more personalized approach to cardiac care for patients.

The Company’s first application of its vector-based technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The HeartBeam system is currently under review with the FDA. The Company has 13 issued US patents and 4 issued international patents supporting the underlying technology.

"The competition this year has been extraordinary, with thousands of submissions from groundbreaking companies worldwide,” said Mark H. Goldstein, Chairman and Founder of The Digital Health Hub Foundation. “We congratulate our winners whose innovations have truly impressed our esteemed panel of judges. The Digital Health Hub Foundation looks forward to witnessing the profound impact our champions continue to make in the healthcare space.”

The Digital Health Hub Foundation’s mission is to support the world’s most innovative healthcare companies in scaling and growing. Since 2017, the 30,000-member community has been dedicated to fostering innovation, including early-to-late-stage healthcare companies, industry providers, payors, mentors, and investors. The annual awards bring together the healthcare industry to celebrate and validate the best of the best in health technology.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement.

For additional information, visit http://www.HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20241024303708r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024303708/en/

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
[e-mail]
www.mzgroup.us

Media Contact:
[e-mail]

Source: HeartBeam, Inc.

[gladeshawk]

NBIO>>>Moving up again. Suggest keeping on your watch lists. HAWK

[ProfitScout]

$BEAT News: HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth

Founder and current CEO Branislav Vajdic named President to focus on advancing the Company’s groundbreaking vector-based technology for heart health, including AI applications

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work towards securing the foundational FDA 510(k) clearance for its vector-based technology and prepares for commercialization and growth.

As part of the long-planned transition, Branislav Vajdic, Ph.D., Founder and current CEO, will move into the role of President. In this role, Dr. Vajdic will focus on further innovating on the Company’s groundbreaking vector-based technology, driving research and development efforts, and advancing artificial intelligence (AI) applications.

“HeartBeam is at an important inflection point and the transition comes at the right time where we can best leverage the unique strengths of each leader. Branislav’s commitment to innovation and vision of providing unprecedented cardiac insights has enabled the Company to reach this pivotal point and we will continue to benefit from his drive to unlock the transformative opportunities ahead. Likewise, Rob has spent his career growing companies with innovative technologies, based on his keen understanding of sales, strategic marketing and go-to-market strategies, while maximizing value for stakeholders, and I am confident that his deep experience will ensure the Company is well positioned for success,” said Rich Ferrari, Executive Chairman, Board of Directors, HeartBeam.

HeartBeam’s core vector-based technology captures the heart’s electrical signals from three dimensions to provide total heart intelligence. The Company’s first application of the technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The HeartBeam system is currently under review with the FDA. The Company has 13 issued U.S. patents and 4 issued international patents supporting the underlying technology.

“The HeartBeam technology is truly transformative and stands to change how cardiac care is managed in the future. We’ve only scratched the surface of unlocking new insights and understanding how our data-rich signals can benefit physicians and patients,” commented Mr. Eno. “I am honored to lead the Company at this exciting time and look forward to my continued partnership with Branislav as we evolve our business and technology to deliver on strategic objectives.”

With over 30 years of experience, Mr. Eno, age 57, is a passionate leader who has created go-to-market strategies for multiple breakthrough products including noninvasive FFRCT for diagnosing coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation, and intravascular brachytherapy. Before joining HeartBeam, Mr. Eno was Chief Executive Officer of Preview Medical, a diagnostic equipment company creating a new category of real-time, in vivo tissue classification for solid tumor cancers, using machine learning and proprietary optical signals. Previously, he was Senior Vice President of Marketing for HeartFlow, leading all aspects of the marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT. He has also held senior marketing and sales leadership roles at OptiMedica, NeoGuide Systems and Avantec Vascular. Mr. Eno holds an MBA from the Stanford Graduate School of Business and a BA, with Honors and Distinction, from Stanford University, where he was Phi Beta Kappa.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement.

For additional information, visit HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20241017992227r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017992227/en/

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
[e-mail]
www.mzgroup.us

Media Contact:
[e-mail]

Source: HeartBeam, Inc.

[Golden Cross]

$ILLR The New Share Structure Is Best Of Any Social Media Stock!

[Golden Cross]

$AGBA $ILLR $4 Billion Merger of AGBA and Triller Now Complete! Very Undervalued here given the current market cap of $ILLR at the time of the merger!

[gladeshawk]

NBIO>>>>Keep on your watch lists. Just a FYI. HAWK

[gladeshawk]

AIRI>>>>NEWS!!! CEO says he will discuss new contracts. Just a FYI, but suggest AIRI be on your watch lists. HAWK

https://finance.yahoo.com/news/air-industries-group-present-microcap-113000525.html

[Jaxon2010]

Hope you’re good down there buddy!!

🙏🙏🙏🙏

[Golden Cross]

$USAU 7 Reasons Why You Should Strongly Consider U.S. Gold Corp. (Nasdaq: USAU) Today!
https://wallstreetnation.com/fast-track-to-production

[Golden Cross]

$AGBA ~ The merger with Triller represents the next step in AGBA’s strategic evolution.

"We aim to become a global powerhouse in digital media surpassing TikTok".

[BLULLISH]

SEE MY POST-https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175183640

[BLULLISH]

CHEAP-**HEALTHCARE BREAKOUT**-STOCK-AMAZING 🤩 CHART— https://www.barchart.com/stocks/quotes/ICBU/opinion

>>>>>>_80%___BUY___RATING_>>>80% big smile

3 MILLION SHARES x .034=$102,000-WOW-BREAKOUT- https://www.stocktitan.net/news/ICBU/i-md-companies-inc-completes-acquisition-of-riize-ulbrsk3t40pj.html


HEALTHCARE ACQUISITION -https://www.tipranks.com/news/press-releases/imd-companies-inc-subsidiary-riize-llc-to-expand-product-line-with-contracted-telemedicine-doctors

TICKER $ICBU

3 MILLION SHARES x .034=$102,000-WOW-BREAKOUT

AMAZING 🤩 CHART— https://www.barchart.com/stocks/quotes/ICBU/opinion

>>>>>>_80%___BUY___RATING_>>>80% big smile

WEEEE-IT’COMING-https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175182932

[Magnum7419]

as predicted $AHRO will grow fast !

[toastturtle]

$BKTPF news today. Confirmed record date for Makinita Resources Spinout. Current Volume leader on CSE, up over 20% so far. Worth a look for either a trade or for the free shares. The record date is October 29th. Probably need to have the shares by the 27th so they will be settled and in your account.... GL.

[Golden Cross]

$AGBA Chart is on a solid uptrend heading into next week. The PSAR flipped bullish last week. The RSI had a bullish cross and the MACD also had a bullish cross last week! Large move brewing here!

[Golden Cross]

$AGBA Looking for merger to complete as soon as next week! Shareholder approved. New Ticker will be $ILLR and the new company will trade as Triller Group, Inc.

[Covid19freak]

ATRA -MC $44 m - FDA Decision in January if the orphan drug gets approved the company will get $60 million milestone payment

Tab-cel® U.S. BLA Accepted Under Priority Review With PDUFA Action Date of January 15, 2025

Atara received a $20 million milestone payment from Pierre Fabre Laboratories in August 2024, following the acceptance of the tab-cel BLA, with the potential to receive a $60 million milestone payment from Pierre Fabre contingent upon FDA approval of the tab-cel BLA

[Solarman]

$MVCO and $MMMW with great business developments. $MMMW with about $1 million market cap and patent pending solar cost cutting technology

[Golden Cross]

$XXII FDA modified tobacco risk designation...95 percent less nicotine.

[ProfitScout]

$IDVV News: International Endeavors Corp. Announces Corporate Update

Las Vegas, Nevada--(Newsfile Corp. - September 18, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced the following update regarding progress made in its products and services.

Winners Waygers AI

The Winners Waygers beta service has been a success. Recently it has surpassed 4000 subscribers for its AI beta mode, and has crossed 50 subscribers for its professional service. We still anticipate reaching up to 100 pro subscribers by year end.

We are planning a couple things in the short term.

1) A video demonstration of how professionals use the AI
2) Development of a section on the site that allows pros to publish their picks to paid subscribers, creating additional revenue for WITech.

AI and Futures Trading

We are proud to announce that we have revived the AI trading service. The project was slowed down by previous management due to volatility and the resources required. Recent events such as the new ETF listings have allowed us to revive the project. We are currently developing an automated trader that trades listed ETFs as well as futures including the Mini and Micro S&P. We anticipate the service being available in November of this year.

WITech Professional Services

The WITech division of IDVV has been servicing several clients, providing custom automation and bots in Financial, and Health & Wellness sectors. We have expanded to the medical sector and are currently working on an LOI for the development of AI tools we believe will help scientists in R&D stages of drug development.

We encourage everyone to follow us.

Twitter
https://twitter.com/IDVVcorp

Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com

About Us

International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com

Disclaimer

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

International Endeavors Corporation
Phone: [phone]
Email: [e-mail]

SOURCE: International Endeavors Corporation, Inc.

https://images.newsfilecorp.com/files/10187/223748_db14adfaa4a0cb5b_logo.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223748

SOURCE International Endeavors Corporation

https://api.newsfilecorp.com/newsinfo/223748/130

[Golden Cross]

💫 $XXII Solid bottom here and ready for a bounce! Think we can see a double here soon!

[Golden Cross]

$AGBA and TRILLER SOON TO BE TRADED ON NASDAQ UNDER TICKER "ILLR"
SHAREHOLDERS MEETING TO BE HELD ON SEPTEMBER 19, 2024

[ProfitScout]

$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series

CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.

In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.

“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”

Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.

Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”

The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.

About Metavesco

Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.

About Local Choice and Striped Pig Distillery

The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.

Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405

For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/

Safe Harbor Statement

This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.

CONTACT:
[e-mail]
[phone]

[BLULLISH]

BOOOM—ALERT-HEALTHCARE-STOCK-BREAKOUT—ACQUISITION ANNOUNCEMENT—https://www.tipranks.com/news/press-releases/imd-companies-inc-signs-letter-of-intent-to-acquire-healthcare-company-riize-llc

ACQUISITION-COMPLETED AS PROMISED-https://www.tipranks.com/news/press-releases/imd-companies-inc-completes-acquisition-of-riize-llc

MAJOR ACQUISITION EXPANSION UPDATES COMING FAST-https://www.tipranks.com/news/press-releases/imd-companies-inc-subsidiary-riize-llc-to-expand-product-line-with-contracted-telemedicine-doctors

AMAZING CHART-$ICBU— https://www.barchart.com/stocks/quotes/ICBU/opinion

[gladeshawk]

MVIS>>>Risky buy big reward possible. Has run up to $28 in the past. Keep on your watch lists. HAWK

[Magnum7419]

ty...

"AHRO is a Kraken just woken. The base in the stock is so SOLID and ready to make new 52 week highs. The upcoming fundamentals that are brewing are OUTSTANDING and will take the stock to much higher prices after making the new 52 week high."

AHRO overview

1. Two major partners for their APP and OTT platform in Whale Echo and Hisense.
2. 4th quarter revenue explosion coming with profitability on the horizon
3. Several other content partnerships in the works.
4. 5% commission on all business with the "As Seen on TV" shopping channel,
5. Upcoming subscription revenue for a soon to be launched VOD (Video on Demand) and KOD (Karaoke on Demand)
6. Broadcasting in 43 markets vs 21 12 months ago
7. Recent "insert ad" rate card increase
8. Vast Tag ad program days away from launch to an audience of 200 MM people
9. Pay Per View channel completed and in discussions with several event promoters for PPV.
10. Authentic Heroes subsidiary around the corner from getting a major JV partner o roll out what will be one of the hottest things to hit the "Merch" market in music and sports.
......

[Golden Cross]

Looking great AHRO

[Magnum7419]

$AHRO is ready to fly IMHO

[toastturtle]

$BKTPF Spin-out expected this quarter. The project being spun out is the Hector Silver and Cobalt project. New Company will be Makinita. Shareholders of record will receive shares of the new company. This is trading under 3 cents so probably a lot more upside than down side at this point. Cruz is also drilling phase 5 on their lithium asset here in 2024 and will complete the maiden resource estimate on the Solar Lithium project. This is a trade, should do well. https://www.stockwatch.com/News/Item/Z-C!CRUZ-3597149/C/CRUZ

[gladeshawk]

MVIS>>>>Just a FYI to keep on your watch lists. HAWK

[linkvest]

ASII... HUGE NEWS> https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175041997

Penny Land here we come

[toastturtle]

$SNNAF News: Increased Stonesthrow project size up to ~32k acres. Highly prospective for Gold, located bordering Ramp Metals Inc. who had some fantastic results recently and has received a 4.5 million investment from Eric Sprott. Company says more news is coming as well as marketing over the next 2 months so worth a look for a trade.

[ProfitScout]

$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

MIAMI, Sept. 3, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company") and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a presenting companies at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024.

The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.

Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will provide an overview of the Company's business during the presentation.

If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference.

Event: H.C. Wainwright 26th Annual Global Investment Conference

Date: September 9-11, 2024

Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person at the Lotte New York Palace Hotel, New York, NY.

Access to the presentation can also be found at https://ir.nrxpharma.com/events beginning at 7:00AM ET Monday September 9, 2024.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About H.C. Wainwright & Co.

H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
[e-mail]

Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
[e-mail]


https://c212.net/c/img/favicon.png?sn=CL96063&sd=2024-09-03 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-announce-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-september-9-11-2024-302236168.html

SOURCE NRx Pharmaceuticals, Inc.

[ProfitScout]

$NRXP News: HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

$30 million Term Sheet from qualified lender for non-dilutive financing for first clinic acquisitions; anticipated closing within 60 days

Executed Non-Binding Term Sheet with initial clinic partners generating annual revenue of over $10 million, with additional partners to be selected under this initial funding agreement

Company projects annualized revenues of $100 million through continued acquisition by mid 2025

Additional information to be presented at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024

MIAMI, Aug. 26, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("HOPE," the "Company"), a medical and technology driven company, today announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, the Company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. The Company anticipates potential operations in the United States, France, and the United Kingdom.

The non-dilutive acquisition funding announced today is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange.

Ketamine is increasingly used to treat suicidal depression, treatment resistant depression (TRD) and Post Traumatic Stress Disorder (PTSD). Until now there has been no unified entity organized around delivering consistent outpatient care for suicidal depression, TRD and PTSD that combines pharmaceutical therapy, FDA approved and proven medical technologies such as Transcranial Magnetic Stimulation (TMS), digital therapeutics and access to clinical trial protocols for the newest potential treatments, delivered by properly licensed medical professionals to optimize care of people with these conditions. Collectively, these conditions represent a crisis that results in the death of someone around the globe every minute. HOPE aims to bring a unified, patient-centric and science-based approach to the care of patients and their families.

"HOPE is dedicated to providing an accessible platform to help caregivers address the critical needs of those suffering from suicidal thoughts, TRD, PTSD and related challenges. We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care and demonstrate best-practices for mental health professionals around the world," said Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "These clinics, and others under review, are planned to provide the foundation for a network generating revenue of approximately $100 million annually in the coming year."

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-potential-acquisition-and-financing-agreements-for-30-million-in-currently-operating-interventional-psychiatry-clinics-302230157.html

SOURCE NRx Pharmaceuticals, Inc.

[ProfitScout]

$SHOT News: Safety Shot Releases Second Quarter 2024 Results and Corporate Highlights

- Q2 Revenues Increased 40%
- Q2 Operating Expenses Decreased 17.7%
- Recent Clinical Trial Confirms Dramatic Reduction of Blood Alcohol Content
- Revolutionary Formula to be Soon Released in Convenient 4-ounce Bottles
- Powdered Version of Alcohol-reducing Nutraceutical to be Released in Q4

JUPITER, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the Company) the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, has released its financial results for its second quarter ended June 30, 2024 as well as a corporate highlights for the quarter.

"We are very excited about our financial performance and our achievements for the second quarter of 2024. A dramatic increase in our revenues with a dramatic decrease in our operating expenses only showcases Safety Shot’s determination to bring value to stakeholders,” stated CEO Jarrett Boon. “We have exciting things expected in the next couple of quarters and believe they will serve as catalysts to further strengthen the company’s financial results going forward. As we continue to execute our business strategy, we remain focused on enhancing our growth potential. This is illustrated by the promising clinical results the company reported this month as well as new partnerships and new product lines the company will be launching in the near future.”

Second Quarter 2024 Highlights:

Company reports a 40% increase in sales in the second quarter compared to the first quarter.
Company reports a 17.7% decrease in operating expenses in the second quarter compared to the first quarter, highlighting significant progress in Safety Shot’s financial health.

Company reveals significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC. Within 30 minutes of consuming Safety Shot, participants showed a 30%-50% faster rate of alcohol reduction compared to the placebo group. Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is now clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.

Company is advancing several product formats and formulations to continue to offer a wide array of products that can be purchased at various locations that coincide with consumer shopping habits.

Company announced that its revolutionary formula will be released in new, convenient 4-ounce bottles. Designed for easy on-the-go use, this new format ensures that customers can enjoy the benefits of Safety Shot's groundbreaking formula anytime, anywhere. The 4-ounce bottles are anticipated to launch in Q3.

Company’s R&D team has successfully found a powdered solution that maintains 100% of the efficacy of the world’s first alcohol-reducing product. Safety Shot will offer a convenient stick pack in Q4.

Company announced a partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States.
Company announced a strategic partnership with Mr. Checkout, a national network of independent distributors, full-line grocery distributors, and wagon-jobbers. This partnership marks a significant milestone in Safety Shot's mission to provide a revolutionary solution for responsible alcohol consumption to the masses. Additional partnerships include GoPuff, BevMo, and more.

About Safety Shot, Inc.

Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot’s ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled “Risk Factors” in Safety Shot’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.

Media and Investor Contact:

Autumn Communications
Jess Weinberger
Phone: [phone]
Email: [e-mail]

Investor Relations
Medon Michaelides
Phone: [phone]
Email: [e-mail]

https://www.globenewswire.com/newsroom/ti?nf=OTIwNjE3NCM2NDI3Njg3IzUwMDExNzExOA==
https://ml.globenewswire.com/media/YzBjY2FmNDAtMzk3My00YTg1LWIxZTYtNzc2MmNmNTM2MTMwLTUwMDExNzExOA==/tiny/Safety-Shot-Inc-.png

Source: Safety Shot, Inc.

[ProfitScout]

$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content

First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content

JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.

The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.

"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.

Key Findings:

Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.

Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."

For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.

About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.

About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com

Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.

https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html

SOURCE Safety Shot

[gladeshawk]

AIRI>>>>Good numbers out today. PPS has made nice 2-3x moves up in the recent past with good news. Suggest keeping on your watch lists. Just a FYI. HAWK

[linkvest]

IGPK... THIS IS HUGE : Jun Fenghuang Group Experiencing Rapid Growth and Expansion... -- https://finance.yahoo.com/news/jun-fenghuang-group-experiencing-rapid-140000992.html

This is huge coming from the company:
The company is committed to consolidating all its divisions under one Jun Fenghuang Group, currently represented by the publicly traded OTC markets ticker IGPK, until the ticker is formally changed to JFHE.
JFH Digital E-Commerce Co., LTD is dedicated to listing on NASDAQ upon completing the merger of all its divisions.

Waiting on the name and symbol ticker to JFHE .......

Up 51% today because of NEWS PR released

[ProfitScout]

$NRXP News: HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff

Petition for a temporary restraining order brought by Streeterville Capital, LLC seeking injunctive relief to prevent spinoff of 49% of HOPE Therapeutics shares to current NRx Shareholders has been denied by Utah arbitrator.

Petition by Streeterville Capital, LLC seeking injunctive relief to prevent sales of NRx shares has been denied by Utah arbitrator.

NRx to proceed with spinoff of HOPE Therapeutics as previously announced.

RADNOR, Pa., July 29, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced the issuance of an order by a Utah arbitrator denying the petition of Streeterville Capital, LLC to enjoin NRx's planned spinoff of 49% of the shares in HOPE Therapeutics to current shareholders of NRx pharmaceuticals. While the proposed spinoff remains subject to compliance with certain disclosure and other requirements under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, the spinoff is intended to provide NRx shareholders with an opportunity to participate in the anticipated value created as a result of the spinoff and to enable a potential listing of HOPE Therapeutics (currently a wholly-owned subsidiary of NRx) on a national securities exchange. The arbitrator also denied Streeterville's petition to enjoin NRx from selling additional shares of NRx stock to finance ongoing operations.

(PRNewsfoto/NRx Pharmaceuticals)

"As we have previously shared with the public, HOPE Therapeutics is in the process of developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression. This arbitration decision enables us to keep our promise to shareholders to spin out 49% of HOPE Therapeutics shares held by NRx to our shareholders, subject to approval by our Board of Directors and compliance with applicable law. We appreciate the support and loyalty of our shareholders as we work to bring HOPE to life," said Prof. Jonathan Javitt, Founder and Chairman of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-nasdaqnrxp-announce-arbitration-order-enabling-hope-therapeutics-spinoff-302208316.html

SOURCE NRx Pharmaceuticals, Inc.

[Golden Cross]

$LDSN LUDUSON G INC. Announces Plans to Enhance Metaverse Experience in Latest Development Project
https://finance.yahoo.com/news/luduson-g-inc-otc-ldsn-140000815.html

[ProfitScout]

$AVRW: We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Source:
https://www.accesswire.com/864776/avenir-wellness-solutions-reports-fourth-quarter-2023-results

[toastturtle]

$SNNAF just announced summer marketing programs with two marketing companies. Life Water and Hillside. Up 15% to 0.033 on the news with a double likelihood. Seems like an easy trade right now. I expect lots of catalysts over the summer here so worth a look. You don't pay for marketing if you don't have something to talk about. Good things coming. GL all.

[ProfitScout]

$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.

This has been pre-announced in the last two IVDN news releases:

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html

[gladeshawk]

QS >>> Just signed new deal with Volkswagen. Suggest keeping on your watch lists. HAWK

[Golden Cross]

$IFUS Largest Volume in 5 Months = Follow_The_Money!

[nickeli54]

🔥 $AAGC 🔥 Conference call folks!

🔥🔥 $AAGC 🔥🔥 Conference call folks!! 💪💪 https://t.co/DDdqNdtXFE

— Nickeli (@nickeli54) July 9, 2024

[nickeli54]

🔥$AAGC 🔥 Mega Thread! 💪

@HStarcuts 🔥🔥🔥 $AAGC 🔥🔥🔥🧵 Folks let’s take a look at where we are here:
✅ MC= $1M
✅ SS = 1.7B OS
✅ No Dilution
✅ No RS Stated many times
✅ Share buybacks monthly
✅ New Locations opening
✅ Audit underway
✅ Qtr over Qtr growth 🔥
✅Annual showed massive growth YOY pic.twitter.com/Bdy0upLSV5

— Nickeli (@nickeli54) July 9, 2024

[nickeli54]

🔥 $AAGC 🔥

💥 $AAGC 💥 Only takes one stock folks to change your life! 8’s hitting 🔥 patience usually plays well if it’s a 💎 Just have to peel back the onion to see what’s inside and this play is as clean as it gets! Take a peek at this annual and note share buy backs 👀 💎🔥💪 pic.twitter.com/kThR84MOuA

— Nickeli (@nickeli54) July 8, 2024